Correspondence 0001213900-22-076845 from Jin Medical International Ltd. (ZJYL)
Jin Medical International Ltd.
Date: Dec. 1, 2022 · CIK: 0001837821 · Accession: 0001213900-22-076845
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-259767
Referenced dates: November 21, 2022
Letter
Via Edgar Division of Corporation Office of Life Sciences Amendment No. 8 to Registration Statement on Form F-1 Filed November 17, 2022 File No. 333-259767
Re: Jin Medical International Ltd.
Dear Ms. Park:
This letter is in response to the letter dated November 21, 2022, from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) addressed to Jin Medical International Ltd. (the “Company”, “we”, or “our”). For ease of reference, we have recited the Commission’s comments in this response. An amendment to the registration statement on Form F-1 (the “Amendment”) is being filed to accompany this letter.
Amendment No. 8 to Form F-1 filed November 17, 2022
Exhibits
1. We note your disclosure on the cover page that your offering is contingent upon final approval of your Nasdaq listing. Please ensure the disclosure is consistent with your underwriting agreement.
Response: The Company acknowledges the Staff’s comment and revised the underwriting agreement, which is being refiled as exhibit 1.1 to the Amendment, to ensure that the disclosure is consistent with the underwriting agreement.
We appreciate the assistance the Staff has provided with its comments. If you have any questions, please do not hesitate to call our counsel, Ying Li, Esq., of Hunter Taubman Fischer & Li LLC, at (212) 530-2206.
Very truly yours,
/s/ Erqi Wang
Show Raw Text
CORRESP
1
filename1.htm
December 1, 2022
Via Edgar
Ms. Jane Park
Division of Corporation
Office of Life Sciences
U.S. Securities and Exchange Commission
Re:
Jin Medical International Ltd.
Amendment No. 8 to Registration Statement on Form F-1
Filed November 17, 2022
File No. 333-259767
Dear Ms. Park:
This letter is in response to the letter dated
November 21, 2022, from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) addressed
to Jin Medical International Ltd. (the “Company”, “we”, or “our”). For ease of reference, we have
recited the Commission’s comments in this response. An amendment to the registration statement on Form F-1 (the “Amendment”)
is being filed to accompany this letter.
Amendment No. 8 to Form F-1 filed November
17, 2022
Exhibits
1.
We note your disclosure on the cover page that your offering is contingent upon final approval of your Nasdaq listing. Please ensure the disclosure is consistent with your underwriting agreement.
Response: The Company acknowledges the
Staff’s comment and revised the underwriting agreement, which is being refiled as exhibit 1.1 to the Amendment, to ensure that the
disclosure is consistent with the underwriting agreement.
We appreciate the assistance the Staff has provided
with its comments. If you have any questions, please do not hesitate to call our counsel, Ying Li, Esq., of Hunter Taubman Fischer &
Li LLC, at (212) 530-2206.
Very truly yours,
/s/ Erqi Wang
Name:
Erqi Wang
Title:
Chief Executive Officer
Cc: Ying Li, Esq.
Hunter Taubman Fischer & Li LLC